Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Lara Goldstein

UK To Fund Development Of Awakn's Ketamine-Assisted Therapy Program For Alcohol Use Disorder In US And UK

Biotech therapeutics company Awakn Life Sciences Corp. (OTCQB:AWKNF) will receive funding from national agency Innovate UK destined to identifying the quickest and most cost-effective route to market in the UK and the US for Awakn's lead program: proprietary ketamine-assisted therapy for treating alcohol use disorder (AUD). 

The initiative is led jointly by the Centre for Process Innovation (CPI) and the Association of British HealthTech Industries (ABHI). 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.